Annica R. Stull-Lane

Annica R. Stull-Lane

Auto-generated profile, based on publicly available information

Annica R. Stull-Lane

Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2024 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
KLKristen L. Lokken-Toyli
Kristen L. Lokken-Toyli
VDVladimir E. Diaz-Ochoa
Vladimir E. Diaz-Ochoa
LCLizbeth Camacho
Lizbeth Camacho
ASAnnica R. Stull-Lane
Annica R. Stull-Lane
AHAmber E. R. Van Hecke
Amber E. R. Van Hecke
RTRenée M. Tsolis
Renée M. Tsolis
In sub-Saharan Africa, multidrug-resistant non-typhoidal Salmonella serovars are a common cause of fatal bloodstream infection. Malnutrition is a predisposing factor, but the underlying mechanisms are unknown. Here we show that vitamin A deficiency, one of the most prevalent micronutrient deficits afflicting African children, increases susceptibility to disseminated non-typhoidal Salmonella disease in mice and impairs terminal neutrophil maturation. Immature neutrophils had reduced expression of Slc11a1, a gene that encodes a metal ion transporter generally thought to restrict pathogen growth in macrophages. Adoptive transfer of SLC11A1-proficient neutrophils, but not SLC11A1-deficient neutrophils, reduced systemic Salmonella burden in Slc11a1−/− mice or mice with vitamin A deficiency. Loss of terminal granulopoiesis regulator CCAAT/enhancer-binding protein ϵ (C/EBPϵ) also decreased neutrophil-mediated control of Salmonella, but not that mediated by peritoneal macrophages. Susceptibility to infection increased in Cebpe−/−Slc11a1+/+ mice compared with wild-type controls, in an Slc11a1-expression-dependent manner. These data suggest that SLC11A1 deficiency impairs Salmonella control in part by blunting neutrophil-mediated defence.

2 October 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
ASAnnica R. Stull-Lane
Annica R. Stull-Lane
KLKristen L. Lokken-Toyli
Kristen L. Lokken-Toyli
VDVladimir E. Diaz-Ochoa
Vladimir E. Diaz-Ochoa
GWGregory T. Walker
Gregory T. Walker
SCStephanie A. Cevallos
Stephanie A. Cevallos
RTRenée M. Tsolis
Renée M. Tsolis
Disseminated disease from non-typhoidal Salmonella enterica strains results in >20% mortality globally. Barriers to effective treatment include emerging multidrug resistance, antibiotic treatment failure, and risk factors such as malnutrition and related micronutrient deficiencies. Individuals in sub-Saharan Africa are disproportionately affected by non-typhoidal S. enterica bloodstream infections. To inform a clinical trial in people, we investigated vitamin A as a treatment in the context of antibiotic treatment failure in a mouse model of vitamin A deficiency. Vitamin A-deficient (VAD) mice exhibited higher systemic bacterial levels with a multidrug-resistant clinical isolate in comparison to mice on a control diet. Sex-specific differences in vitamin A deficiency and disseminated infection with S. enterica serotype Typhimurium (S. Typhimurium) were observed. VAD male mice had decreased weight gain compared to control male mice. Further, infected VAD male mice had significant weight loss and decreased survival during the course of infection. These differences were not apparent in female mice. In a model of disseminated S. Typhimurium infection and antibiotic treatment failure, we assessed the potential of two consecutive doses of vitamin A in alleviating infection in male and female mice on a VAD or control diet. We found that subtherapeutic antibiotic treatment synergized with vitamin A treatment in infected VAD male mice, significantly decreasing systemic bacterial levels, mitigating weight loss and improving survival. These results suggest that assessing vitamin A as a therapy during bacteremia in malnourished patients may lead to improved health outcomes in a subset of patients, especially in the context of antibiotic treatment failure. Non-typhoidal Salmonella serotypes generally cause diarrhea in people. However, there are certain factors that make people at risk of developing a more severe infection where the bacteria can enter the blood and cause fever and whole-body symptoms. Patients with this infection are usually hospitalized, and about one in five patients do not survive. The factors that make this bloodstream infection possible include pathogen features like resistance to antibiotics and patient factors like a malnourished state. Better treatments are needed. In this study, the authors assess vitamin A as a treatment during antibiotic treatment failure in a mouse model. Vitamin A-deficient male mice have better outcomes with vitamin A and antibiotic co-therapy, whereas female mice do not benefit. Despite similar levels of bacteria causing infection systemically, female mice show better outcomes in terms of weight loss and survival than male mice overall. This research provides evidence that a clinical study assessing vitamin A as a treatment in people could lead to improved survival for malnourished patients presenting with severe bloodstream infection.

30 March 2026 in JID Innovations
Verified
Journal Article
Open access
XCXizhao Chen
Xizhao Chen
KKKevin Kuonqui
Kevin Kuonqui
SPSarit Pal
Sarit Pal
JSJinyeon Shin
Jinyeon Shin
ASAnnica Stull-Lane
Annica Stull-Lane
RKRaghu P Kataru
Raghu P Kataru
Keratinocytes, once viewed as inert epidermal scaffolds, are now recognized as active participants in the cutaneous immunity. They orchestrate local immune responses by releasing cytokines, chemokines, and alarmins that shape innate and adaptive inflammation. Dysregulated keratinocyte-immune interactions underline chronic inflammatory skin disorders, such as atopic dermatitis, psoriasis, and cutaneous lupus erythematosus. More recently, keratinocytes have been identified as key contributors to secondary lymphedema, a chronic inflammatory and fibrotic condition historically attributed to lymphatic dysfunction. This review revises our understanding of keratinocytes as immunomodulatory cells, while focusing primarily on their emerging role in the pathogenesis of secondary lymphedema. We highlight and appraise recent evidence that lymphatic stasis reprograms keratinocyte differentiation, induces type 2 helper T cells-skewed inflammatory responses, and perpetuates chronic inflammation and fibrosis. Understanding this keratinocyte-immune-lymphatic axis may unveil novel therapeutic targets beyond traditional lymphangiogenic approaches.

1 June 2026 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
HPHyeung Ju Park
Hyeung Ju Park
SPSarit Pal
Sarit Pal
XCXizhao Chen
Xizhao Chen
JSJinyeon Shin
Jinyeon Shin
GNGabriela D. García Nores
Gabriela D. García Nores
RKRaghu P Kataru
Raghu P Kataru
Background: Secondary lymphedema is a common complication of cancer treatment and epidermal changes are recognised as histological hallmarks of secondary lymphedema; however, the role of keratinocytes in the pathophysiology of this disease remains unclear. Methods: Hyperkeratosis, up‐regulation of protease‐activated receptor 2 (PAR2) and Th2‐inducing cytokines were assessed in biopsy specimens from patients with unilateral breast cancer‐related lymphedema (BCRL) and in a mouse model of lymphedema. PAR2 inhibition using global PAR2 knockout, keratinocyte‐specific PAR2 KO and bone marrow chimera models, or keratinocyte proliferation inhibition using a topical formulation of Teriflunomide (TF), was analysed in mouse models of lymphedema. We also assessed the direct effects of patient‐derived lymphedema lymph fluid (LF) on keratinocyte activation in vitro. Results: Hyperkeratosis, expression of Th2‐inducing cytokines and PAR2 were significantly increased in BCRL patient biopsies and mouse models. Keratinocytes play a primary role in the lymphedema development by producing T helper 2 (Th2)‐inducing cytokines. Specifically, keratinocyte proliferation and PAR2 expression are early responses following lymphatic injury and regulate the expression of Th2‐inducing cytokines, the migration of Langerhans cells and the infiltration of Th2‐differentiated T cells into the skin. Deficiency of PAR2 or topical inhibition of thymic stromal lymphopoietin rescues secondary lymphedema by reducing Th2 inflammation. Inhibition of PAR2 activation with a small‐molecule inhibitor, or the proliferation of the inhibitor TF, prevents activation of keratinocytes stimulated with lymphedema fluid. Finally, topical TF is highly effective in reducing swelling, fibrosis and inflammation and the overall pathology of lymphedema. Conclusions: Our findings suggest that lymphedema is a chronic inflammatory skin disease, and topically targeting keratinocyte inhibition may be a clinically effective therapy for this condition. Key points: Activated keratinocytes play a key role in the pathophysiology of secondary lymphedema through PAR2 by producing Th2‐inducing cytokines that modulate skin inflammatory responses.

31 July 2026 in Skin Health and Disease
Verified
Journal Article
Open access
BPBracha L Pollack
Bracha L Pollack
ARArielle N Roberts
Arielle N Roberts
BWBenjamin D Wagner
Benjamin D Wagner
GAGopika Ashokan
Gopika Ashokan
XCXizhao Chen
Xizhao Chen
RKRaghu P Kataru
Raghu P Kataru
T helper type 2 (Th2)-mediated inflammatory skin diseases, including atopic dermatitis, discoid lupus erythematosus, systemic sclerosis, autoimmune bullous diseases and secondary lymphoedema, demonstrate significant racial and ethnic disparities in prevalence, severity and clinical outcomes. These disorders share pathogenic mechanisms involving Th2-driven immune activation, fibrosis and epidermal barrier dysfunction, leading to chronic inflammation and substantial morbidity. Black and Hispanic populations consistently experience greater disease burden, more severe clinical manifestations and reduced quality of life compared with White patients, reflecting complex interactions between biologic and socioeconomic factors. Current molecular and immunological studies suggest that ancestry-associated differences in immune polarization, cytokine signalling, autoantibody expression, fibrotic pathways and epidermal barrier biology may contribute to variation in disease phenotype and severity across Th2-mediated disorders. Black patients have demonstrated enhanced Th2 and Th22-mediated inflammation, increased IgE production, elevated interleukin (IL)-4, IL-13 and IL-22 signalling, and distinct genetic and serological profiles, including variation in filaggrin-related barrier proteins and autoantibody expression. However, mechanistic studies directly evaluating race-associated Th2 immune responses remain limited in many inflammatory skin diseases, and under-representation of diverse populations in translational research and clinical trials continues to restrict understanding of disease biology and therapeutic response. This review synthesizes the current epidemiological, molecular and immunological evidence linking race, immune dysregulation and disease heterogeneity across Th2-mediated skin disorders. Together, these findings support a growing framework in which ancestry-associated differences in immune regulation and social determinants jointly shape disparities in Th2-mediated inflammatory skin disease.